Text Size

Customized Acoustic Stimulation for Long Term Medical Benefit for the Relief of Tinnitus and Hyperacusis (CALM)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by Neuromonics, Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Neuromonics, Inc.
ClinicalTrials.gov Identifier:
NCT00730834
First received: August 5, 2008
Last updated: August 24, 2009
Last verified: August 2009
History of Changes
  Purpose

Neuromonics TInnitus Treatment CALM study is a multi site study of 100 adult subjects with clinically significant disturbing tinnitus to evaluate outcome measures using the FDA cleared Neuromonics treatment after 6, 12, 24 and 36 months. Patients must be meet certain inclusion criteria and they are also required to pay for the all costs of the treatment. Subjects will be provided a modest participation fee at 6, 12, 24 and 36 months upon completion of patient questionnaires (subjects must have access to a computer and internet in order to complete on line questionnaires).


Condition Intervention Phase
Tinnitus
Hyperacusis
 Device: Oasis
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 4 Study of Use of a Customized Acoustic Stimulus to Reduce the Disturbing Symptoms of Tinnitus and Hyperacusis

Resource links provided by NLM:

MedlinePlus related topics: Tinnitus
U.S. FDA Resources

Further study details as provided by Neuromonics, Inc.:

Primary Outcome Measures:
  • Pre and post treatment scores on Tinnitus reaction questionnaire [ Time Frame: 6, 12, 24, 36 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Tinnitus Handicap Inventory, Hospital Anxiety and Depression Scale, [ Time Frame: 6, 12, 24, 36 months ] [ Designated as safety issue: No ]

Enrollment: 53
Study Start Date: June 2007
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Oasis
    Digital sound player that provides customized acoustic stimulus based on subjects hearing thresholds
    Other Name: Neuromonics Oasis Tinnitus Treatment
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18 years of age,
  • TRQ of at least 17 or above,
  • Able to pay for the treatment,
  • Not using any other treatment for tinnitus,
  • Access to computer and internet,
  • Compliant patient

Exclusion Criteria:

  • Hearing PTA > 50 dB, score on HADS of greater than 11 on the anxiety and depression scale,
  • Not willing to follow the protocol
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00730834

Locations
United States, Florida
Silverstein Ear Institute
Sarasota, Florida, United States, 34239
Sponsors and Collaborators
Neuromonics, Inc.
  More Information

Additional Information:
Related Info  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Jack Wazen, MD, Silverstein ear institute
ClinicalTrials.gov Identifier: NCT00730834     History of Changes
Other Study ID Numbers: CALM Study, 20071022
Study First Received: August 5, 2008
Last Updated: August 24, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Neuromonics, Inc.:
tinnitus
ringing in the ears
buzzing
static
hyperacusis
 loudness discomfort
Clinically
significant
discomfort

Additional relevant MeSH terms:
Hyperacusis
Tinnitus
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
 Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on June 18, 2013